Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The high throughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms. Tools employing MERFISH will advance data-driven drug discovery and development and enable new insights for clinical pathology and diagnostics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/30/20 | $14,000,000 | Series A |
ARCH Venture Partners Northpond Ventures | undisclosed |
| 04/07/21 | $37,000,000 | Series B |
ARCH Venture Partners David Walt Northpond Ventures Novalis LifeSciences Pura Vida Investments Tao Capital Partners | undisclosed |
